Mary Louise Affronti | Scholars@Duke

Mary Louise Affronti
Associate Professor in the School of Nursing

Dr. Mary Lou Affronti is an Associate Professor who joined the Duke University School of Nursing faculty in February 2014. She earned both her DNP and her MSN at DUSON, and additionally earned a Master’s degree in Health Science in Clinical Research from the Duke University School of Medicine. She holds a Clinical Associate faculty appointment in the Duke University Medical Center Department of Surgery /Neurosurgery. She is also Primary Investigator and Adult Nurse Practitioner at the Preston Robert Tisch Brain Tumor Center in the Duke Cancer Institute.

Dr. Affronti has been a part of Duke’s oncology clinical and research community for almost three and a half decades, and has been associated with DUSON since 1989 in a variety of roles, including clinical associate, guest lecturer, preceptor, and clinical instructor. She was instrumental in developing the oncology curriculum for DUSON nurse practitioner students. In 2005, she was honored by the Friends of Nursing at Duke with the Evelyn Morgan Award for Excellence in Oncology Nursing. Dr. Affronti’s DNP capstone on adherence to antiemetic guidelines in patients with malignant glioma, received the Outstanding Capstone Doctoral Project Award in 2013, was published in Supportive Care in Cancer and was cited in a 2016 New England Journal of Medicine Antiemetic Review Article. Dr. Affronti was the Recipient of the Southern Nursing Research Society Clinical Research Award in 2018.

Dr. Affronti has been developing and leading therapeutic and supportive care research while seeing patients as a nurse practitioner, and is continuing both her clinical and research activities at the Brain Tumor Center. She has a strong interest in the development and testing of therapies and supportive care for primary brain tumors as a currently a co-principal or principal investigator on many Phase II clinical trials at the Duke Brain Tumor Center.

Current Appointments & Affiliations

Associate Professor in the School of Nursing, School of Nursing, Duke University 2015

Contact Information

047 Baker House, Durham, NC 27710
Box 3624 Med Ctr, Durham, NC 27710
affro002@mc.duke.edu (919) 684-5301
My CV 2018
My Google Scholar profile
My Researchgate Profile

Background
Education, Training, & Certifications
- M.S.N., Duke University 1986
- B.S., University of Delaware 1983
Duke Appointment History
- Instructor, Temporary in the School of Nursing, School of Nursing, Duke University 2014 - 2015
- Clinical Associate in the School of Nursing, School of Nursing, Duke University 2004 - 2014
- Clinical Associate in the Department of Surgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2007 - 2014
- Clinical Associate in the Department of Surgery, Surgery, Clinical Science Departments 1999 - 2007
- Clinical Associate in the School of Nursing, School of Nursing, Duke University 2000 - 2004
- Clinical Associate in the School of Nursing, School of Nursing, Duke University 1994 - 1999
Recognition
Awards & Honors
- Recipient of the Southern Nursing Research Society Clinical Research Award. Southern Nursing Research Society. 2018
Expertise
Subject Headings
Global Scholarship
- Expertise
  - United States of America (Country)
- Research
  - United States of America (Country)
- Teaching
  - United States of America (Country)
Research
Selected Grants
- Phase II randomized study to evaluate efficacy, patient satisfaction, and compliance of Rolapitant plus ondansetron 2017 - 2022
- Graduate Scholarship in Cancer Nursing Practice - Michl 2019 - 2021
- Graduate Scholarship in Cancer Nursing Practice - Kafkas 2018 - 2020
- HIV Nurse Practitioner Training Program 2013 - 2018
- Graduate Scholarship in Cancer Nursing Practice - Herndon 2015 - 2017
- Temozolomide Resistance in CNS Tumors awarded by National Institutes of Health 1999 - 2001
- Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Randazzo, D. M., F. McSherry, J. E. Herndon, M. L. Affronti, E. S. Lipp, C. Flahiff, E. Miller, et al. “Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.” Complementary Therapies in Clinical Practice 36 (August 1, 2019): 43–48. https://doi.org/10.1016/j.ctcp.2019.05.002.
    Full Text
  - Affronti, Mary Lou. “Introduction..” Semin Oncol Nurs 34, no. 5 (December 2018): 417–19. https://doi.org/10.1016/j.soncn.2018.10.003.
    Full Text Link to Item
  - Affronti, Mary Lou, Jennifer Gamboa Jackman, Frances McSherry, James E. Herndon, Elwood C. Massey, Eric Lipp, Annick Desjardins, et al. “Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma..” Oncologist 23, no. 8 (August 2018): 889-e98. https://doi.org/10.1634/theoncologist.2018-0149.
    Full Text Link to Item
  - Cone, Christina K., and Mary Lou Affronti. “Development of a Professional Practice Model for Neuro-oncology Advanced Practitioners at an Academic Medical Center: A Quality Improvement Project..” Journal of the Advanced Practitioner in Oncology 9, no. 5 (July 2018): 475–86.
  - Clark-Snow, Rebecca, Mary Lou Affronti, and Cynthia N. Rittenberg. “Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses..” Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 26, no. 2 (February 2018): 557–64. https://doi.org/10.1007/s00520-017-3866-6.
    Full Text
  - Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population..” J Neurooncol 134, no. 2 (September 2017): 363–69. https://doi.org/10.1007/s11060-017-2535-4.
    Full Text Link to Item
  - Affronti, Mary Lou, Sarah Woodring, Katherine B. Peters, James E. Herndon, Frances McSherry, Patrick N. Healy, Annick Desjardins, James J. Vredenburgh, and Henry S. Friedman. “A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab..” Ther Clin Risk Manag 13 (2017): 33–40. https://doi.org/10.2147/TCRM.S122480.
    Full Text Link to Item
  - Affronti, Mary Lou, Susan M. Schneider, James E. Herndon, Susan Schlundt, and Henry S. Friedman. “Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice..” Support Care Cancer 22, no. 7 (July 2014): 1897–1905. https://doi.org/10.1007/s00520-014-2136-0.
    Full Text Link to Item
  - Affronti, Mary Lou, and Joseph Bubalo. “Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy..” Cancer Management and Research 6 (January 2014): 329–37. https://doi.org/10.2147/CMAR.S68102.
    Full Text
  - Affronti, Mary Lou, Christopher R. Heery, James E. Herndon, Jeremy N. Rich, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman. “Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy..” Cancer 115, no. 15 (August 1, 2009): 3501–11. https://doi.org/10.1002/cncr.24398.
    Full Text Link to Item
  - Allen, Deborah, Susanne Jackson, Karen Ziegler, Steve Silverman, Kara Penne, and Mary Lou Affronti. “Prevalence of diabetes mellitus in adult patients with primary gliomas on steroid therapy.” Neuro Oncology 9, no. 4 (October 1, 2007): 567–68.
    Link to Item
  - Bota, Daniela A., Annick Desjardins, Jennifer A. Quinn, Mary L. Affronti, and Henry S. Friedman. “Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas..” Therapeutics and Clinical Risk Management 3, no. 5 (October 2007): 707–15.
  - Vredenburgh, J. J., B. Madan, D. Coniglio, M. Ross, G. Broadwater, D. Niedzwiecki, J. Edwards, et al. “A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy..” Bone Marrow Transplant 37, no. 11 (June 2006): 1009–15. https://doi.org/10.1038/sj.bmt.1705367.
    Full Text Link to Item
  - Vredenburgh, James J., David Coniglio, Gloria Broadwater, Roy B. Jones, Maureen Ross, Elizabeth J. Shpall, Atif Hussein, et al. “Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone..” Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 12, no. 2 (February 2006): 195–203. https://doi.org/10.1016/j.bbmt.2005.10.009.
    Full Text
  - Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James Vredenburgh, Sridharan Gururangan, et al. “Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma..” Neuro Oncol 6, no. 2 (April 2004): 145–53. https://doi.org/10.1215/S1152851703000498.
    Full Text Link to Item
  - Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James Vredenburgh, John H. Sampson, James M. Provenzale, et al. “Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma..” Neuro Oncol 6, no. 2 (April 2004): 134–44. https://doi.org/10.1215/s1152851703000413.
    Full Text Link to Item
  - Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon, et al. “Phase II trial of temozolomide in patients with progressive low-grade glioma..” J Clin Oncol 21, no. 4 (February 15, 2003): 646–51. https://doi.org/10.1200/JCO.2003.01.009.
    Full Text Link to Item
  - Gururangan, S., L. Cokgor, J. N. Rich, S. Edwards, M. L. Affronti, J. A. Quinn, J. E. Herndon, et al. “Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas..” Neuro Oncol 3, no. 4 (October 2001): 246–50. https://doi.org/10.1093/neuonc/3.4.246.
    Full Text Link to Item
  - Rizzieri, D. A., J. J. Vredenburgh, R. Jones, M. Ross, E. J. Shpall, A. Hussein, G. Broadwater, et al. “Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support..” J Clin Oncol 17, no. 10 (October 1999): 3064–74. https://doi.org/10.1200/JCO.1999.17.10.3064.
    Full Text Link to Item
  - Kurtzberg, J., M. J. Laughlin, C. A. Smith, D. A. Rizzieri, J. J. Vredenburgh, M. E. Lassiter, M. L. Affronti, et al. “Hematopoietic recovery in adult recipients following unrelated umbilical cord blood (UCB) transplantation..” Blood 90, no. 10 (November 15, 1997): 480–480.
    Link to Item
  - Hussein, A. M., W. P. Petros, M. Ross, J. J. Vredenburgh, M. L. Affrontil, R. B. Jones, E. J. Shpall, et al. “A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies..” Cancer Chemother Pharmacol 37, no. 6 (1996): 561–68.
    Link to Item
  - Cartee, L., W. P. Petros, G. L. Rosner, C. Gilbert, S. Moore, M. L. Affronti, J. A. Hoke, A. M. Hussein, M. Ross, and P. Rubin. “Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study..” Cytokine 7, no. 5 (July 1995): 471–77.
    Link to Item
  - VREDENBURGH, J., B. WATERSPICK, S. DRAGO, M. L. AFFRONTI, J. KURTZBERG, M. ROSS, A. HUSSEIN, et al. “G-CSF-PRIMED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPCS) COLLECTED IN THE STEADY-STATE ARE SUPERIOR TO G-CSF-PRIMED PBPCS COLLECTED ON THE REBOUND FROM CHEMOTHERAPY.” Blood 84, no. 10 (November 15, 1994): A107–A107.
    Link to Item
  - Vandemark, R. M., E. J. Shpall, and M. L. Affronti. “Bone metastases from breast cancer: value of CT bone windows..” Journal of Computer Assisted Tomography 16, no. 4 (July 1992): 608–14.
  - Shpall, E. J., R. B. Jones, R. C. Bast, G. L. Rosner, R. Vandermark, M. Ross, M. L. Affronti, C. Johnston, S. Eggleston, and M. Tepperburg. “4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial..” J Clin Oncol 9, no. 1 (January 1991): 85–93. https://doi.org/10.1200/JCO.1991.9.1.85.
    Full Text Link to Item
  - Jones, R. B., E. J. Shpall, J. Shogan, M. L. Affronti, D. Coniglio, L. Hart, E. Halperin, J. D. Iglehart, J. Moore, and J. Gockerman. “The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer..” Cancer 66, no. 3 (August 1, 1990): 431–36. https://doi.org/10.1002/1097-0142(19900801)66:3<431::aid-cncr2820660305>3.0.co;2-x.
    Full Text Link to Item
  - Jones, R. B., E. J. Shpall, M. Ross, D. Coniglio, M. L. Affronti, and W. P. Peters. “High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity..” Cancer Chemother Pharmacol 26, no. 2 (1990): 155–56.
    Link to Item
  - Shpall, E. J., I. C. Anderson, R. C. Bast, W. T. Joines, R. B. Jones, M. Ross, S. Edwards, S. Eggleston, C. Johnston, and M. Tepperberg. “Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation..” Prog Clin Biol Res 333 (1990): 321–35.
    Link to Item
  - Peters, W. P., A. Stuart, M. L. Affronti, C. S. Kim, and R. E. Coleman. “Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans..” Blood 72, no. 4 (October 1988): 1310–15.
- Conference Papers
  - Affronti, Mary Lou, Dina Randazzo, Eric S. Lipp, Katherine B. Peters, Susan C. Herndon, Sarah Woodring, Patrick Healy, Christina K. Cone, James E. Herndon, and Susan M. Schneider. “Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma..” In Semin Oncol Nurs, 34:472–85, 2018. https://doi.org/10.1016/j.soncn.2018.10.006.
    Full Text Link to Item
  - Peters, Katherine B., Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E. Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Henry S. Friedman, and Annick Desjardins. “INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS.” In Neuro Oncology, 19:170–170. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Peters, Katherine B., Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E. Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Henry S. Friedman, and Annick Desjardins. “MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB.” In Neuro Oncology, 19:206–206. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Randazzo, Dina, Frances McSherry, James E. Herndon, Mary Lou Affronti, Patrick Healy, Eric S. Lipp, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “A SINGLE INSTITUTION'S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA.” In Neuro Oncology, 19:202–202. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Peters, Katherine, Mary Lou Affronti, Sarah Woodring, Janet Minchew, Eric Lipp, Frances McSherry, James Herndon, et al. “NEUROCOGNITION IN LOW-GRADE GLIOMAS: ASSOCIATIONS WITH MEASURABLE AND PERCEIVED IMPAIRMENTS.” In Neuro Oncology, 18:122–122. OXFORD UNIV PRESS INC, 2016.
    Link to Item
  - Randazzo, Dina, Frances McSherry, James Herndon, Mary Lou Affronti, Eric Lipp, Charlene Flahiff, Elizabeth Miller, et al. “A CROSS-SECTIONAL STUDY OF DISTRESS THROUGHOUT THE DISEASE TRAJECTORY IN PRIMARY BRAIN TUMOR PATIENTS.” In Neuro Oncology, 18:160–160. OXFORD UNIV PRESS INC, 2016.
    Link to Item
  - Affronti, Mary Lou, Sarah Woodring, Karen Allen, John Kirkpatrick, Katherine B. Peters, James E. Herndon, Frances McSherry, et al. “Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)..” In Support Care Cancer, 24:4365–75, 2016. https://doi.org/10.1007/s00520-016-3276-1.
    Full Text Link to Item
  - Randazzo, Dina, and Katherine B. Peters. “Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients..” In Cns Oncol, 5:241–49, 2016. https://doi.org/10.2217/cns-2016-0010.
    Full Text Link to Item
  - Rittenberg, C., R. Clark-Snow, and M. L. Affronti. “Impact of chemotherapy-induced nausea and vomiting (CINV) on emergency department (ED) visits and disruption of chemotherapy: results of a survey of oncology nurses.” In Annals of Oncology, Vol. 27. Oxford University Press (OUP), 2016. https://doi.org/10.1093/annonc/mdw390.12.
    Full Text
  - Clark-Snow, Rebecca Anne, Cynthia N. Rittenberg, and Mary Lou Affronti. “Results of a survey of oncology nurses assessing practice patterns and adherence to antiemetic guidelines..” In Journal of Clinical Oncology, 34:e21647–e21647. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e21647.
    Full Text
  - Kim, Jung-Young, Sarah Woodring, Mary Lou Affronti, Dina Randazzo, Frances McSherry, James Emmett Herndon, Eric S. Lipp, et al. “Secondary cancers in long-term survivors of primary glioblastoma..” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Peters, Katherine B., Sarah Woodring, Mary Lou Affronti, Frances McSherry, James Emmett Herndon, Annick Desjardins, Tulika Ranjan, Gordana Vlahovic, Allan H. Friedman, and Henry S. Friedman. “Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study..” In Journal of Clinical Oncology, 32:9519–9519. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.9519.
    Full Text
  - Affronti, Mary Lou, Susan Schneider, James Herndon, Susan Schlundt, and Henry Friedman. “ADHERENCE TO ANTIEMETIC GUIDELINES IN PATIENTS WITH MALIGNANT GLIOMA: TRANSLATING EVIDENCE INTO PRACTICE.” In Oncology Nursing Forum, 40:E426–27. ONCOLOGY NURSING SOC, 2013.
    Link to Item
  - Peters, Katherine, Sarah Woodring, Mary Lou Affronti, Stevie Threatt, Scott Lindhorst, Danijela Levacic, Annick Desjardins, et al. “NEUROCOGNITIVE DYSFUNCTION IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA PATIENTS: UTILIZATION OF STANDARDIZED COMPUTERIZED NEUROCOGNITIVE TESTING.” In Neuro Oncology, 15:96–96. OXFORD UNIV PRESS INC, 2013.
    Link to Item
  - Affronti, Mary Lou, Sarah Woodring, James E. Herndon, Frances McSherry, Katherine B. Peters, Henry S. Friedman, Annick Desjardins, et al. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” In Neuro Oncology, 14:156–156. OXFORD UNIV PRESS INC, 2012.
    Open Access Copy Link to Item
  - Affronti, Mary Lou, Alise Brickhouse, Jennifer Marcello, James Herndon, David A. Reardon, Annick Desjardins, and James J. Vredenburgh. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” In Neuro Oncology, 11:656–656. DUKE UNIV PRESS, 2009.
    Link to Item
  - Affronti, Mary Lou, Cindy Bohlin, Karen Bronson, Lee Jones, James Herndon, Jennifer Quinn, David Reardon, et al. “Phase II trial of Zoledronic Acid (ZA) for bone loss prevention in glioma patients.” In Neuro Oncology, 9:566–566. DUKE UNIV PRESS, 2007.
    Link to Item
  - Allen, Deborah, Karen Carter, Cindy Bohlin Karen Bronson, Lee Jones, Stephen Keir, Bebe Guill, Renee Raynor, Bart Bridigi, Mary Lou Affronti, and James Vredenburgh. “Efficacy of dronabinol for nausea, vomiting, and appetite disturbances in adult patients with primary malignant gliomas.” In Neuro Oncology, 9:567–567. DUKE UNIV PRESS, 2007.
    Link to Item
  - Affronti, Mary Lou, Jeannette M. Dowell, James E. Herndon, Joan Cahill, Jeremy N. Rich, Jennifer A. Quinn, David A. Reardon, et al. “Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy.” In Neuro Oncology, 8:437–437. DUKE UNIV PRESS, 2006.
    Link to Item
  - Allen, D. H., K. Carter, S. Jackson, K. Ziegler, M. L. Affronti, R. Dunn, and B. Guill. “Evaluating impact of symptom management on quality of life in glioma patients.” In Neuro Oncology, 6:355–355. DUKE UNIV PRESS, 2004.
    Link to Item
  - PETERS, W. P., D. P. RODEHEAVER, D. B. MENZEL, R. J. HERFKENS, T. M. BASHORE, M. L. AFFRONTI, K. VANECEK, et al. “EFFECT OF HIGH-DOSE ALKYLATING-AGENTS ON ENDOMYOCARDIAL GLUTATHIONE LEVELS AND CARDIAC-PERFORMANCE IN MAN.” In Proceedings of the American Association for Cancer Research, 29:268–268. AMER ASSOC CANCER RESEARCH, 1988.
    Link to Item
Teaching & Mentoring
Recent Courses

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Awards & Honors

Subject Headings

Global Scholarship

Expertise

Research

Teaching

Selected Grants

Selected Publications

Academic Articles

Conference Papers

Recent Courses